Guiding Competitive Binding Assays Using Protein-Protein Interaction Prediction: The HER2-Affitin Use Case.

ABSTRACT: Affitins are a class of small artificial proteins, designed as alternatives to antibodies for therapeutic, diagnostic, and biotechnological applications. Recent patents by Bracco Imaging S.p.A have demonstrated the potential of two engineered affitins for designing imaging probes to detect and monitor human epidermal growth-factor receptor 2 (HER2) levels in vivo. Targeting HER2 is critical, as its overexpression is linked to poor prognosis of several cancer diseases, making it a key marker for treatment strategies and diagnostic tools. Interestingly, these affitins do not compete with the commonly used monoclonal antibodies trastuzumab and pertuzumab for HER2 binding sites, allowing their concurrent use in vivo and making them suitable for imaging or diagnostic purposes. Sin

SUBMITTER: Ranaudo A 

PROVIDER: S-EPMC11656212 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature